NASDAQ:SNCE Science 37 (SNCE) Stock Price, News & Analysis → Biden to Drop BOMBSHELL June 13th? (From Paradigm Press) (Ad) Free SNCE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.75▼$5.7550-Day Range$5.68▼$5.7552-Week Range$3.73▼$12.96VolumeN/AAverage Volume43,227 shsMarket Capitalization$34.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Science 37 alerts: Email Address Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. About Science 37 Stock (NASDAQ:SNCE)Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina. As of March 11, 2024, Science 37 Holdings, Inc. operates as a subsidiary of eMed, LLC.Read More Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. SNCE Stock News HeadlinesMay 13 at 8:24 PM | markets.businessinsider.comScience 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and ComplianceMay 13 at 8:00 AM | globenewswire.comScience 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and ComplianceMay 9, 2024 | globenewswire.comScience 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”May 2, 2024 | globenewswire.comScience 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical TrialApril 17, 2024 | markets.businessinsider.comScience 37 Provides Fully Consented Patients to Sites to Supplement EnrollmentApril 17, 2024 | globenewswire.comScience 37 Provides Fully Consented Patients to Sites to Supplement EnrollmentMarch 12, 2024 | prnewswire.comeMed completes tender offer for all outstanding shares of Science 37February 27, 2024 | businesswire.comSCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCEFebruary 12, 2024 | finance.yahoo.comeMed commences tender offer for Science 37February 10, 2024 | businesswire.comSCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCEFebruary 10, 2024 | markets.businessinsider.comScience 37 Initiates Cost-Cutting, Workforce Reduction PlanFebruary 4, 2024 | morningstar.comScience 37 Holdings Inc SNCEFebruary 1, 2024 | benzinga.comScience 37 Hldgs Stock (NASDAQ:SNCE) Dividends: History, Yield and DatesJanuary 31, 2024 | stockhouse.comShareholder Alert: Ademi LLP investigates whether Science 37 Holdings, Inc. has obtained a Fair Price in its transaction with eMedJanuary 30, 2024 | msn.comScience 37 Issues Regulation FD Informational DisclosureJanuary 30, 2024 | msn.comScience 37 Announces Upcoming Merger Agreement ExecutionJanuary 30, 2024 | realmoney.thestreet.comScience 37 just downgraded at Craig-Hallum, here's whyJanuary 29, 2024 | stockhouse.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Science 37 Holdings, Inc. BuyoutJanuary 29, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Science 37 (SNCE), Avid Bioservices (CDMO)January 29, 2024 | benzinga.comCrude Oil Down Over 1%; Science 37 Holdings Shares Spike HigherJanuary 29, 2024 | tmcnet.comSNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Science 37 Holdings, Inc. Is Fair to ShareholdersJanuary 29, 2024 | finanznachrichten.deScience 37, Inc.: Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating EnrollmentJanuary 29, 2024 | marketwatch.comScience 37 Shares Rise on Deal to Be AcquiredDecember 28, 2023 | seekingalpha.comNDRA, LITM and SNCE among mid-day moversDecember 13, 2023 | investorplace.comSNCE Stock Earnings: Science 37 Hldgs Beats EPS, Beats Revenue for Q3 2023See More Headlines Receive SNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolNASDAQ:SNCE CUSIPN/A CIK1819113 Webwww.lifesciacquisition.com Phone984-377-3737FaxN/AEmployees460Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($21.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,990,000.00 Net Margins-206.86% Pretax Margin-207.00% Return on Equity-83.09% Return on Assets-61.58% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual Sales$60.26 million Price / Sales0.57 Cash FlowN/A Price / Cash FlowN/A Book Value$16.70 per share Price / Book0.34Miscellaneous Outstanding Shares5,970,000Free Float5,564,000Market Cap$34.33 million OptionableNot Optionable Beta0.55 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. David Coman (Age 54)CEO & Director Comp: $796.13kMs. Christine A. Pellizzari J.D. (Age 56)Chief Legal & Human Resources Officer and Secretary Comp: $521.58kMs. Darcy Forman (Age 48)Chief Delivery Officer Comp: $550.58kMr. Mike Zaranek (Age 53)Chief Financial Officer Irena LambridisVP and Head of Quality Assurance & ComplianceMs. Margie Gimbel KoomanVice President of Marketing & CommunicationsMr. Drew BustosChief Strategy & Marketing OfficerMr. Jonathan Cotliar M.D. (Age 52)Chief Medical Officer Comp: $486.6kMr. Michael Shipton (Age 52)Chief Commercial Officer Mr. Tyler Van HornVP of Corporate Strategy & Chief of StaffMore ExecutivesKey CompetitorsForianNASDAQ:FORABrainstorm Cell TherapeuticsNASDAQ:BCLISpruce BiosciencesNASDAQ:SPRBFortress BiotechNASDAQ:FBIOBriaCell TherapeuticsNASDAQ:BCTXView All Competitors SNCE Stock Analysis - Frequently Asked Questions Should I buy or sell Science 37 stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNCE, but not buy additional shares or sell existing shares. View SNCE analyst ratings or view top-rated stocks. When did Science 37's stock split? Science 37 shares reverse split on Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. This page (NASDAQ:SNCE) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 Tech Stocks to Buy for 2024Daily Market AlertsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Science 37 Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.